Citigroup Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.8
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a 'Buy' rating on ProQR Therapeutics (NASDAQ:PRQR) but lowers the price target from $2.1 to $1.8.
September 18, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a 'Buy' rating on ProQR Therapeutics but lowers the price target from $2.1 to $1.8.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term value of the stock. However, the impact is not necessarily negative as the 'Buy' rating is still in place.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100